Financial Statements 111 23 POST-RETIREMENT BENEFITS CONTINUED Reserves Included within the retained earnings reserve is the actuarial reserve.
Movements on this reserve are as follows: 2005 2004 2003 $m $m $m At 1 January 303 167 Actuarial losses 35 179 240 Deferred tax 10 43 73 At 31 December 328 303 167 24 EMPLOYEE COSTS AND SHARE OPTION PLANS FOR EMPLOYEES Employee costs The average number of people employed by the Group is set out in the table below.
In accordance with the Companies Act 1985, this includes part-time employees: Employees 2005 2004 2003 Average number of people employed by the Group in: UK 11,600 11,500 11,100 Continental Europe 26,200 25,600 23,900 The Americas 17,900 18,500 17,900 Asia, Africa & Australasia 9,200 8,600 8,100 Continuing operations 64,900 64,200 61,000 The number of people employed by the Group at the end of 2005 was 65,300 2004 64,200, 2003 62,600.
The costs incurred during the year in respect of these employees were: 2005 2004 2003 $m $m $m Salaries 4,270 4,078 3,587 Social security costs 670 644 526 Pension costs 265 280 281 Other employment costs 556 450 489 5,761 5,452 4,883 Severance costs of $29m are not included above 2004 $nil, 2003 $nil.
The Directors believe that, together with the basic salary system, the Groups employee incentive schemes provide competitive and market-related packages to motivate employees.
They should also align the interests of employees with those of shareholders, as a whole, through long term share ownership in the Company.
The Groups current UK, Swedish and US schemes are described below: other arrangements apply elsewhere.
AstraZeneca Annual Report and 112 Form 20-F Information 2005 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 24 EMPLOYEE COSTS AND SHARE OPTION PLANS FOR EMPLOYEES CONTINUED The AstraZeneca UK Performance Bonus Plan Employees of participating AstraZeneca UK companies are invited to participate in this bonus plan, which rewards strong individual performance.
Bonuses are paid partly in the form of Ordinary Shares in the Company under the Inland Revenue-approved AstraZeneca All-Employee Share Plan and up to a maximum annual value of 3,000 and partly in cash.
A tax-efficient share retention scheme, under which employees leave their bonus shares in trust for three to five years, forms part of the All-Employee Share Plan.
The Company also offers UK employees the opportunity to buy Partnership Shares Ordinary Shares under the All-Employee Share Plan.
Employees may invest up to 1,500 over a 12 month accumulation period and purchase Partnership Shares in the Company with the total proceeds at the end of the period.
The purchase price for the shares is the lower of the price at the beginning or the end of the 12 month period.
A tax efficient share retention scheme is also available in respect of Partnership Shares.
At the Companys AGM in 2002, shareholders approved the issue of new shares for the purposes of the All-Employee Share Plan.
The AstraZeneca Executive Annual Bonus Scheme This scheme is a performance bonus scheme for Directors and senior employees who do not participate in the AstraZeneca UK Performance Bonus Plan.
Annual bonuses are paid in cash and reflect both corporate and individual performance measures.
The Remuneration Committee has discretion to reduce or withhold bonuses if business performance falls sufficiently short of expectations in any year such as to make the payment of bonuses inappropriate.
The AstraZeneca Savings-Related Share Option Scheme and the AstraZeneca Savings-Related Share Option Plan UK employees may make regular monthly savings contributions over a three or five year period and may apply for options to acquire AstraZeneca Ordinary Shares.
Further details are set out below.
The AstraZeneca Share Option Plan This is a share option plan for employees of participating AstraZeneca Group companies which was approved by shareholders at the Companys AGM in 2000.
The first grant of options occurred in August 2000.
The main grant of options in 2005 under the plan was in March, with a further smaller grant in August.
The Remuneration Committee sets the policy for the Companys operation of the plan and, in accordance with the rules of the plan, conducted a review of the plan in 2004.
The AstraZeneca Performance Share Plan This plan was approved by shareholders in 2005 for a period of 10 years.
Generally, awards can be granted at any time, but not during a close period of the Company.
The first grant of awards was made in June 2005.
Thereafter, the majority of awards are likely to be granted at or around the same time as options are granted under the AstraZeneca Share Option Plan.
Awards granted under the plan vest after three years depending on the performance of the Company compared to that of a selected peer group of other pharmaceutical companies.
The Remuneration Committee has responsibility for agreeing any awards under the plan and for setting the policy for the way in which the plan should be operated, including agreeing performance targets and which employees should be invited to participate.
A fuller description of this plan can be found on page 73 in the Directors Remuneration Report.
Sweden In Sweden an all-employee performance bonus plan is in operation, which rewards strong individual performance.
Bonuses are paid partly in the form of Ordinary Shares in the Company and partly in cash.
Existing Ordinary Shares purchased in the market are used to pay bonuses awarded under the plan.
The AstraZeneca Executive Annual Bonus Scheme and the AstraZeneca Share Option Plan both operate in respect of relevant AstraZeneca employees in Sweden.
US In the US, there are two all-employee performance bonus plans in operation, which reward strong individual performance.
There are also two senior staff incentive schemes, under which approximately 140 participants are awarded either AstraZeneca ADSs or stock appreciation rights related to AstraZeneca ADSs.
AstraZeneca ADSs necessary to satisfy the awards are purchased in the market.
The AstraZeneca Share Option Plan operates in respect of relevant AstraZeneca employees in the US.
Share option plans At 31 December 2005, there were options outstanding under the Zeneca 1994 Executive Share Option Scheme, the Astra Shareholder Value Incentive Plan, the AstraZeneca Savings-Related Share Option Scheme, the AstraZeneca Savings-Related Share Option Plan and the AstraZeneca Share Option Plan.
1 Summary of the AstraZeneca Share Option Plan Eligibility Any AstraZeneca employee may be recommended from time to time for the grant of an option.
The Remuneration Committee sets the policy for the Companys operation of the plan including as regards which employees will be eligible to participate.
Grant of options Options may be granted at any time other than during a close period.
The grant of options is supervised by the Remuneration Committee, which is comprised wholly of Non-Executive Directors.
No payment is required for the grant of an option.
Options may be granted over AstraZeneca Ordinary Shares or ADSs.
Financial Statements 113 24 EMPLOYEE COSTS AND SHARE OPTION PLANS FOR EMPLOYEES CONTINUED Acquisition price The price per Ordinary Share payable upon the exercise of an option will not be less than an amount equal to the average of the middle-market closing price for an Ordinary Share or ADS of the Company on the London or New York Stock Exchange on the three consecutive dealing days immediately before the date of grant or as otherwise agreed with HM Revenue & Customs.
Where the option is an option to subscribe, the price payable upon exercise cannot be less than the nominal value of an Ordinary Share of the Company.
Exercise of options An option will normally be exercisable between three and 10 years following its grant provided any relevant performance condition has been satisfied.
Options may be satisfied by the issue of new Ordinary Shares or by existing Ordinary Shares purchased in the market.
The Remuneration Committee sets the policy for the Companys operation of the plan including as regards whether any performance target s will apply to the grant and or exercise of each eligible employees option.
Options normally lapse on cessation of employment.
Exercise is, however, permitted for a limited period following cessation of employment either for reasons of injury or disability, redundancy or retirement, or at the discretion of the Remuneration Committee, and on an amalgamation, take-over or winding-up of the Company.
2 Summary of the AstraZeneca Savings-Related Share Option Scheme and the AstraZeneca Savings-Related Share Option Plan The AstraZeneca Savings-Related Share Option Scheme was approved by shareholders in 1994 for a period of 10 years.
The last grant of options under this scheme was made in September 2002.
In 2003, shareholders approved the AstraZeneca Savings-Related Share Option Plan for a period of 10 years.
The first grant of options under this plan was made in September 2003.
The following sections apply to both the AstraZeneca Savings-Related Share Option Scheme and the AstraZeneca Savings-Related Share Option Plan, which have broadly similar rules.
Eligibility UK-resident employees of participating AstraZeneca companies are automatically eligible to participate.
Grant of options Invitations to apply for options may be issued within six weeks after the announcement by the Company of its results for any period and at other times in circumstances considered to be exceptional by the Directors.
No invitations may be issued later than 10 years after the approval of the scheme by shareholders.
Options may only be granted to employees who enter into HM Revenue & Customs-approved savings contracts with the savings body nominated by the Company, under which monthly savings of a fixed amount currently not less than 5 nor more than 250 are made over a period of three or five years.
The number of Ordinary Shares over which an option is granted will be such that the total amount payable on its exercise will be the proceeds on maturity of the related savings contract.
No payment will be required for the grant of an option.
Individual participation Monthly savings by an employee under all savings contracts linked to options granted under any Save As You Earn scheme may not exceed 250 or such lower amounts as may be determined by the Directors.
Acquisition price The price per Ordinary Share payable upon the exercise of an option will not normally be less than the higher of: a 90% of the arithmetical average of the middle-market quotations for an Ordinary Share on the London Stock Exchange on three consecutive dealing days shortly before the date on which invitations to apply for options are issued provided that no such day may fall before the Company last announced its results for any period or such other dealing day or days falling within the six week period for the issue of invitations, as the Directors may decide: and b the nominal value of an Ordinary Share unless the option is expressed to relate only to existing Ordinary Shares.
Exercise of options An option will normally be exercisable only for six months commencing on the third or fifth anniversary of the commencement of the related savings contract.
Options are satisfied by the issue of new Ordinary Shares.
Exercise is, however, permitted for a limited period irrespective of the period during which the option has been held following cessation of employment in certain compassionate circumstances or where an option has been held for more than three years except on dismissal for misconduct and on an amalgamation, take-over or winding-up of the Company.
AstraZeneca Annual Report and 114 Form 20-F Information 2005 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 24 EMPLOYEE COSTS AND SHARE OPTION PLANS FOR EMPLOYEES CONTINUED 3 Summary of the Zeneca 1994 Executive Share Option Scheme The Zeneca 1994 Executive Share Option Scheme was introduced in 1994.
The last date for the grant of options was 16 March 2000 and the scheme has been replaced by the AstraZeneca Share Option Plan.
Options granted under the 1994 scheme are normally exercisable between three and 10 years following grant, provided the relevant performance condition has been satisfied.
The performance condition applicable to the 1994 scheme was that earnings per share must have grown by at least the increase in the UK Retail Price Index over three years plus 3% per annum.
Satisfaction of this condition was tested annually by reference to the audited financial statements.
All options granted under the 1994 scheme have become exercisable, the performance conditions having been satisfied.
4 Summary of the Astra Shareholder Value Incentive Plan In 1996, Astra established a stock option plan for some 100 Astra employees in key senior positions.
The plan is no longer used for the grant of options and has been superseded by the AstraZeneca Share Option Plan.
On completion of Astras merger with Zeneca, options in Astra shares granted under the plan were replaced by options to acquire a number of AstraZeneca Ordinary Shares based on the exchange ratio used in the exchange offers used to effect the AstraZeneca merger.
The ratio of AstraZeneca options granted in respect of former Astra options was 0.5045 AstraZeneca options for each Astra option held.
AstraZeneca Share Option Plan 1994 Scheme SAYE Schemes ASVIP Shares Options WAEP Options WAEP Options WAEP under option WAEP 000 pence 000 pence 000 pence 000 SEK At 1 January 2003 Options outstanding 21,398 3347 9,289 2647 4,065 1987 759 391 Movements during 2003 Options granted 15,505 2232 551 2211 Options exercised 52 2468 358 2423 382 2137 151 311 Options forfeited 1,163 3001 571 2695 282 2192 1 318 Options lapsed Weighted average fair value of options granted during the year 583 658 At 31 December 2003 Options outstanding 35,688 2874 8,360 2654 3,952 1988 607 411 Movements during 2004 Options granted 10,741 2529 550 2262 Options exercised 329 2787 586 2704 113 2184 114 321 Options forfeited 1,964 2886 285 2660 276 2199 10 474 Options lapsed Weighted average fair value of options granted during the year 650 632 At 31 December 2004 Options outstanding 44,136 2790 7,489 2650 4,113 2005 483 431 Movements during 2005 Options granted 9,621 2133 606 2257 Options exercised 1,053 2486 1,259 2601 689 1782 6 442 Options forfeited 2,625 2800 272 2688 592 2248 168 411 Options lapsed Weighted average fair value of options granted during the year 619 700 At 31 December 2005 Options outstanding 50,079 2670 5,958 2658 3,438 2053 309 442 Range of exercise prices 1913p to 1337p to 1756p to 442 SEK to 3487p 2749p 2971p 442 SEK Weighted average remaining contractual life 2,655 days 1,453 days 1,047 days 23 days Options exercisable 18,969 3291 5,958 2658 191 2456 309 442 Weighted average exercise price Share options were exercised on a regular basis throughout the period.
Financial Statements 115 24 EMPLOYEE COSTS AND SHARE OPTION PLANS FOR EMPLOYEES CONTINUED The fair value of the options is estimated at the date of grant using the Black-Scholes option pricing model.
The following table gives the assumptions applied to the options granted in the respective periods shown.
Expectations of early exercise are incorporated into the model.
2005 2004 2003 Average share price pence 2384 2439 2442 Weighted average exercise price pence AstraZeneca Share Option Plan 2133 2529 2232 SAYE schemes 2257 2262 2211 Weighted average fair value of options granted in the period pence AstraZeneca Share Option Plan 619 650 583 SAYE schemes 700 632 658 Expected volatility % 30.0 25.0 25.0 Dividend yield % 2.3 2.3 2.0 Risk-free interest rate % 4.3 3.5 4.3 Expected lives: AstraZeneca Share Option Plan years 6.0 6.0 6.0 Expected lives: SAYE schemes years 3.9 3.8 4.3 The expected volatility is based on the historic volatility calculated based on the weighted average remaining life of the share options adjusted for any expected changes to future volatility due to publicly available information.
No other features of options granted were incorporated into the measurement of fair value.
The charge for share-based payments in respect of share options is $128m 2004 $147m, 2003 $154m which is comprised entirely of equitysettled transactions.
AstraZeneca Performance Share Plan Shares WAFV 000 pence Shares awarded in June 2005 312 1121 The fair value was determined using a modified version of the binomial model.
This method incorporated expected dividends but no other features into the measurements of fair value.
US incentive share schemes Shares WAFV 000 $ 1,032 41.77 Weighted average fair value The charge for share-based payments in respect of the AstraZeneca Performance Share Plan and the US incentive share schemes is $15m 2004 $16m, 2003 $9m.
